On September 14, 2026, Xenetic Biosciences, Inc. entered into a Share Exchange Agreement to acquire the entire issued share capital of Santersus AG. This acquisition will enable Xenetic to expand its portfolio and capabilities in the biopharmaceutical sector. The transaction is subject to the satisfaction or waiver of conditions outlined in the Exchange Agreement.
Company Information
Company
Xenetic Biosciences
Location
40 SPEEN STREET, SUITE 102
Framingham, Massachusetts, United States
About
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Don't miss Xenetic Biosciences's next move
Get an email the moment Xenetic Biosciences makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Xenetic Biosciences's next move
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired Santersus AG?
Santersus AG was acquired by Xenetic Biosciences, based in Framingham. The deal was reported on September 16, 2026. Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences is publicly traded (XBIO) and operates in Biotechnology.
When did Xenetic Biosciences acquire Santersus AG?
Xenetic Biosciences's acquisition of Santersus AG was reported on September 16, 2026. On September 14, 2026, Xenetic Biosciences, Inc. entered into a Share Exchange Agreement to acquire the entire issued share capital of Santersus AG. This acquisition will enable Xenetic to expand its portfolio and capabilities in the biopharmaceutical sector. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Santersus AG do?
Zurich-based Santersus AG is a biotechnology company developing NucleoCapture, a novel, patent-protected extracorporeal blood purification technology designed to selectively remove cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs). It is privately held, operating in Biotechnology, and is based in Zurich.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
Framingham
ZurichBiotechnologyBiotechnologyHealth CareMedicalTherapeutics